Abstracts tagged "Biologicals"

Abstract Number: 2358 • ACR Convergence 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Iain McInnes³, M. Elaine Husni⁴, Mitsumasa Kishimoto⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Fabian Proft⁸, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated clinical efficacy and safety to 3 years…
Abstract Number: 2203 • ACR Convergence 2025
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Arshdeep Waring¹, Sofia Rieger-Torres², Jeremiah Tan³, Viktoria Pavlova⁴ and Neda Amiri⁵, ¹University of British Columbia, Abbotsford, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McMaster University, Ancaster, ON, Canada, ⁵University of British Columbia, North Vancouver, BC, Canada
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as ixekizumab and secukinumab, are increasingly used in the treatment of seronegative inflammatory arthritis, including psoriatic arthritis and axial spondyloarthritis.…
Abstract Number: 1656 • ACR Convergence 2025
Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In older adults with rheumatoid arthritis (RA), anti-TNF therapies are typically used as first-line biologic treatment. However, many patients require a switch to non-TNF…
Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Lara Gómez⁹, Kim Hoyt¹⁰, Weibin Bao¹¹ and Karl Gaffney¹², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Farmaceutica, Madrid, Spain, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹²Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
Abstract Number: 1368 • ACR Convergence 2025
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Se Hee Kim¹ and kyung-Ann Lee², ¹Kyung Hee University College of Medicine, Seoul, Republic of Korea, ²Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea
Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
Abstract Number: 1165 • ACR Convergence 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, Jessica A. Walsh², Timothy P. Fitzgerald³, Soumya Chakravarty⁴, Elizabeth Adamson⁵, Bruno Emond⁶, Carmine Rossi⁷, Samuel Schwartzbein⁷, Kana Yokoji⁷, Yuxi Wang⁷, Patrick Lefebvre⁷, Dominic Pilon⁷, Shikha Singla⁸ and Joseph F Merola⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³Johnson & Johnson, Horsham, PA, USA, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Analysis Group, Inc., Montreal, QC, Canada, QC, ⁷Analysis Group, Inc., Montreal, QC, Canada, QC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: A prior analysis found that patients (pts) with psoriatic arthritis (PsA) treated with guselkumab (GUS), an IL-23p19 subunit inhibitor, were approximately 2× more likely…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0886 • ACR Convergence 2025
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA
Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 2477 • ACR Convergence 2025
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giacomo De Luca⁴, Giovanna Cuomo⁵, Lidia P Ananieva⁶, Eric Hachulla⁷, Vanessa Smith⁸, Ana Maria Gheorghiu⁹, Radim Bečvář¹⁰, Patricia E. Carreira¹¹, Nicolas Hunzelmann¹², Daniel Furst¹³, Vera Ortiz-Santamaria¹⁴, Francesco Del Galdo¹⁵, Marco Matucci-Cerinic¹⁶ and Anna-Maria Hoffmann-Vold¹⁷, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Precision Medicine, University Hospital Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁶A Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷University of Lille, LILLE, France, ⁸Ghent University Hospital, Gent, Belgium, ⁹Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹⁰Department of Internal Medicine, Charles University,, Prague, Czech Republic, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹³Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁴HOSP. GENERAL DE GRANOLLERS, Barcelona, Spain, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The therapeutic landscape for systemic sclerosis- interstitial lung disease (SSc-ILD) has rapidly evolved over the past decade, with increasing adoption of immunosuppressive (IST) and…
Abstract Number: 2354 • ACR Convergence 2025
ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
José Miguel Sequí-Sabater¹, Pablo Beltrán Martin-Lorente², Sonia Pastor Navarro³, Maria del Carmen Lopez Gonzalez⁴, Maria Sanchez-Wonenburger⁵, DESAMPARADOS CASADO POVEDA³ and Anna Martínez Cristóbal⁶, ¹La Ribera University Hospital, Rheumatology Department, Gandía, Spain, ²Universidad Católica de Valencia "San Vicente Mártir", Valencia, Comunidad Valenciana, Spain, ³La Ribera University Hospital, Rheumatology Department, Valencia, Comunidad Valenciana, Spain, ⁴La Ribera University Hospital, Rheumatology Department, Cullera, Comunidad Valenciana, Spain, ⁵Hospital Universitario de La Ribera, València, Comunidad Valenciana, Spain, ⁶La Ribera University Hospital, Rheumatology Department, Alzira, Comunidad Valenciana, Spain

Background/Purpose: While traditional analysis relies on statistical software such as SPSS, emerging tools like ChatGPT introduce the possibility of performing statistical tests, interpreting results, and…
Abstract Number: 2143 • ACR Convergence 2025
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Jacqueline Madison¹, Andrew Grim² and Janna Shim³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medicine, Ann Arbor, MI, ³Midwestern University Chicago College of Osteopathic Medicine, Downers Grove
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are rare, chronic, autoinflammatory diseases distinct from other forms of chronic inflammatory arthritis. Potential…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].